| [1] |
Kariyawasan CC, Hughes DA, Jayatillake MM, et al. Multiple myeloma: causes and consequences of delay in diagnosis [J]. QJM, 2007, 100(10): 635-639.
|
| [2] |
Knudsen LM, Hippe E, North M, et al. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. [J]. Eur J Haematol, 1994, 53(4): 207-212.
|
| [3] |
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma [J]. Mayo Clin Proc, 2003, 78(1): 21-24.
|
| [4] |
Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma [J]. Blood Cancer J, 2015, 5(3): e296-e311.
|
| [5] |
Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure [J]. BMC Nephrol, 2008, 9: 11-19.
|
| [6] |
Dispenzieri A, Kyle R, Merlini G, et al.International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders [J]. Leukemia, 2009, 23(2): 215-224.
|
| [7] |
Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure [J]. BMC Nephrol, 2008, 9: 11-20.
|
| [8] |
Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease [J]. Clin J Am Soc Nephrol, 2008, 3(6): 1684-1690.
|
| [9] |
Heher EC, Rennke HG, Laubach JP, et al. Kidney disease and multiple myeloma [J]. Clin J Am Soc Nephrol, 2013, 8(11): 2007-2017.
|
| [10] |
Basnayake K, Ying WZ, Wang PX, et al. Immunoglobulin light chains activate tubular epithelial cells through redox signaling [J]. J Am Soc Nephrol, 2010, 21(7): 1165-1173.
|
| [11] |
Kleber M, Ihorst G, Deschler B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients [J]. Eur J Haematol, 2009, 83(6): 519-527.
|
| [12] |
Cockwell P, Hutchison CA. Management options for cast nephropathy in multiple myeloma [J]. Curr Opin Nephrol Hypertens, 2010, 19(6): 550-555.
|
| [13] |
Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database [J]. Ann Pharmacother, 2005, 39(7-8): 1194-1197.
|
| [14] |
Hiromura K, Nujima Y. Renal disease in multiple myeloma [J]. Nihon Rinsho, 2007, 65(12): 2229-2234.
|
| [15] |
Barlogie B, Shaughnessy J, Tricot S, et al. Treatment of multiple myeloma [J]. Blood, 2004, 103(1): 20-22.
|
| [16] |
Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin -dexamethasone in multiple myeloma: results of a phase II study [J]. J Clin Oncol, 2010, 28(30): 4635-4642.
|
| [17] |
Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase Ⅲ HOVON-65/ GMMG-HD4 trial [J]. J Clin Oncol, 2012, 30(24): 2946-2956.
|
| [18] |
Ballester OF, Tummala R, Janssen WE, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency [J]. Bone Marrow Transplant, 1997, 20(8): 653-666.
|
| [19] |
何东，牛挺．硼替佐米治疗多发性骨髓瘤的应用进展[J]．华西医学，2012，(2): 197-202.
|
| [20] |
Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3，open-label，multicentre study [J]. Lancet Oncol, 2016, 17(1): 27-38.
|
| [21] |
Assi LK, McIntyre N, Fraser S, et al. The association between polyclonal combined serum free light chain concentration and mortality in individuals with early chronic kidney disease [J]. PLoS One, 2015, 10(7): e0129980.
|
| [22] |
Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies [J]. J Am Soc Nephrol, 2007, 18(3): 886-895.
|
| [23] |
Tanner GA, Evan AP, Summerlin PB, et al. Glomerular and proximal tubular morphology after single nephron obstruction [J]. Kidney Int, 1989, 36(6): 1050-1060.
|
| [24] |
Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains [J]. Kidney Int, 2008, 73(11): 1282-1288.
|
| [25] |
Yu X, Gan L, Wang Z, et al. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma：a meta-analysis [J]. Int J Clin Pharmacol Ther, 2015, 53(5): 391-397.
|
| [26] |
Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis [J]. Clin J Am Soc Nephrol, 2009, 4(4): 745-754.
|
| [27] |
Hutchison CA, Cockwell P, Reid S. et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies [J]. J Am Soc Nephrol, 2007, 18(3): 886-895.
|
| [28] |
Martín-Reyes G, Toledo-Rojas R, Torres-de R, et al. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma [J]. Nefrologia (Madr), 2012, 32: 35-43.
|
| [29] |
Hutchison CA, Heyne N, Airia P, et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemo therapy and high cut-off haemodialysis [J]．Nephrol Dial Transplant, 2012, 27(10): 3823-3828.
|
| [30] |
Curti A, Schwarz A, Trachsler J, et al. Therapeutic efficacy and cost effectiveness of high cut-off dialyzers compared to conventional dialysis in patients with cast nephropathy [J]. PLoS One, 2016, 11(7): e0159942.
|
| [31] |
Grima DT, Airia P, Attard C, et al. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney [J]. Curr Med Res Opin, 2011, 27(2): 383-391.
|
| [32] |
Hutchison CA, Cook M, Heyne N, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial [J]. Trials, 2008, 9: 55.
|
| [33] |
Cook M, Hutchison C, Fifer L, et al. High cut-off haemodilysis (HCO-HD)dose not improve outcomes in myeloma cast nephropathy: results of European trial of free light chain removal by extended haemodilysis in cast nephropathy (EULITE) [J]. Adv Chronic Kidney Dis, 2012, 19(5): 333-341.
|
| [34] |
Taheri D, Chehrei A, Fesharakizadeh M, et al. Recurrent multiple myeloma following renal transplantation: a case report [J]. Transplant Proc, 2007, 39(4): 1063-1065.
|
| [35] |
Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-term follow up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease [J]. Transplantation, 201l, 91(6): 672-676.
|